title: Mitomycin C in advanced breast cancer: an update.
abstract: Mitomycin C has a documented response rate of 20% to 30% when used as treatment in advanced breast cancer. Because of its delayed and cumulative hematologic toxicity, there has been a reluctance to use this agent. However, by lowering the drug dosage, the hematologic, pulmonary, and renal toxicities have been reduced. The reduced dosage does not appear to have compromised the treatment results.
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use*
chemical_list: D008937:Mitomycins; D016685:Mitomycin